GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Avant Diagnostics Inc (GREY:AVDX) » Definitions » Altman Z2-Score

Avant Diagnostics (Avant Diagnostics) Altman Z2-Score : -29.33 (As of Apr. 29, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Avant Diagnostics Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Avant Diagnostics has a Altman Z2-Score of -29.33, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Avant Diagnostics's Altman Z2-Score or its related term are showing as below:


Avant Diagnostics Altman Z2-Score Historical Data

The historical data trend for Avant Diagnostics's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avant Diagnostics Altman Z2-Score Chart

Avant Diagnostics Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Sep14 Sep15 Sep16 Sep17 Sep18
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avant Diagnostics Quarterly Data
Jan14 Apr14 Jul14 Oct14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avant Diagnostics's Altman Z2-Score

For the Diagnostics & Research subindustry, Avant Diagnostics's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avant Diagnostics's Altman Z2-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Avant Diagnostics's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Avant Diagnostics's Altman Z2-Score falls into.



Avant Diagnostics Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Avant Diagnostics's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-0.6049+3.26*-6.9254+6.72*-0.5091+1.05*0.6102
=-29.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2018:
Total Assets was $4.91 Mil.
Total Current Assets was $0.06 Mil.
Total Current Liabilities was $3.03 Mil.
Retained Earnings was $-33.98 Mil.
Pre-Tax Income was -0.452 + -0.834 + -0.951 + -0.32 = $-2.56 Mil.
Interest Expense was -0.007 + -0.003 + -0.004 + -0.045 = $-0.06 Mil.
Total Liabilities was $3.03 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.062 - 3.03)/4.907
=-0.6049

X2=Retained Earnings/Total Assets
=-33.983/4.907
=-6.9254

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-2.557 - -0.059)/4.907
=-0.5091

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(1.877 - 0.028)/3.03
=0.6102

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Avant Diagnostics has a Altman Z2-Score of -29.33 indicating it is in Distress Zones.


Avant Diagnostics  (GREY:AVDX) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Avant Diagnostics Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Avant Diagnostics's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Avant Diagnostics (Avant Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
1050 30th Street NW, Suite 107, Washington, DC, USA, 20007
Avant Diagnostics Inc is a medical diagnostic technology company. Business activity of the group is functioned through United States. It focuses on the commercialization of a series of proprietary microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. The company's premier product is OvaDx, a non-invasive proteomics diagnostic screening test for the early detection of ovarian cancer.

Avant Diagnostics (Avant Diagnostics) Headlines